RGEN Repligen Corporation
Repligen Corporation (RGEN) is expected to report earnings on October 27, 2026, before the market open. The consensus earnings estimate is $0.46 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +19.4% since its last earnings release on July 28, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs.
Sector
Healthcare
Industry
Medical Instruments/Supply